Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
KROS Stock Summary
Top 10 Correlated ETFs
KROS
In the News
Keros Therapeutics, Inc. (KROS) is on the Move, Here's Why the Trend Could be Sustainable
Keros Therapeutics, Inc. (KROS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Does Keros Therapeutics, Inc. (KROS) Have the Potential to Rally 35.66% as Wall Street Analysts Expect?
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 35.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Recent Price Trend in Keros Therapeutics, Inc. (KROS) is Your Friend, Here's Why
Keros Therapeutics, Inc. (KROS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts Predict a 45.35% Upside in Keros Therapeutics, Inc. (KROS): Here's What You Should Know
The mean of analysts' price targets for Keros Therapeutics, Inc. (KROS) points to a 45.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Keros Therapeutics To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
LEXINGTON, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that three abstracts will be presented from the KER-012 program at the Pulmonary Vascular Research Institute (“PVRI”) 2024 Annual Congress, to be held from January 31 through February 3, 2024.
Keros Therapeutics, Inc. (KROS) Is a Great Choice for 'Trend' Investors, Here's Why
Keros Therapeutics, Inc. (KROS) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Keros Therapeutics, Inc. (KROS) Just Flashed Golden Cross Signal: Do You Buy?
From a technical perspective, Keros Therapeutics, Inc. (KROS) is looking like an interesting pick, as it just reached a key level of support. KROS's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.
Keros Therapeutics to Present at Upcoming Healthcare Conferences
LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:
Corrected: Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
LEXINGTON, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS) is re-issuing this press release solely to correct inadvertent typographical errors.
Keros Therapeutics to Host Conference Call and Webcast to Provide an Overview of TROPOS, the KER-012 Phase 2 Clinical Trial in Patients with Pulmonary Arterial Hypertension
LEXINGTON, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros will host a conference call and webcast to provide an overview of TROPOS, its global Phase 2 clinical trial to evaluate KER-012 in combination with background therapy in patients with pulmonary arterial hypertension (“PAH”), on August 8, 2023 at 8:00 a.m. Eastern time.
KROS Financial details
KROS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.55 | 0 | 0.86 | 0 | 0.01 | |
Net income per share | -0.68 | -2.93 | -2.52 | -4.15 | -5.2 | |
Operating cash flow per share | -0.88 | -2.38 | -2.66 | -2.78 | -4.23 | |
Free cash flow per share | -0.89 | -2.4 | -2.71 | -2.82 | -4.31 | |
Cash per share | 0.39 | 17.15 | 9.86 | 11.06 | 11.25 | |
Book value per share | 0.3 | 16.88 | 10.42 | 10.99 | 11.28 | |
Tangible book value per share | 0.3 | 16.88 | 10.42 | 10.99 | 11.28 | |
Share holders equity per share | 0.3 | 16.88 | 10.42 | 10.99 | 11.28 | |
Interest debt per share | 0.07 | 0.06 | 0.05 | 0.53 | 0.49 | |
Market cap | 365.24M | 1.09B | 1.37B | 1.21B | 1.17B | |
Enterprise value | 359.5M | 828.84M | 1.14B | 946.29M | 854.11M | |
P/E ratio | -29.59 | -24.11 | -23.24 | -11.58 | -7.65 | |
Price to sales ratio | 36.52 | 0 | 67.92 | 0 | 7.75K | |
POCF ratio | -22.83 | -29.65 | -21.97 | -17.3 | -9.4 | |
PFCF ratio | -22.45 | -29.41 | -21.61 | -17 | -9.22 | |
P/B Ratio | 67 | 4.18 | 5.61 | 4.37 | 3.52 | |
PTB ratio | 67 | 4.18 | 5.61 | 4.37 | 3.52 | |
EV to sales | 35.95 | 0 | 56.53 | 0 | 5.66K | |
Enterprise value over EBITDA | -36.69 | -18.21 | -20.03 | -9.04 | -5.12 | |
EV to operating cash flow | -22.47 | -22.47 | -18.28 | -13.51 | -6.86 | |
EV to free cash flow | -22.1 | -22.29 | -17.99 | -13.27 | -6.73 | |
Earnings yield | -0.03 | -0.04 | -0.04 | -0.09 | -0.13 | |
Free cash flow yield | -0.04 | -0.03 | -0.05 | -0.06 | -0.11 | |
Debt to equity | 0.23 | 0 | 0 | 0.05 | 0.04 | |
Debt to assets | 0.12 | 0 | 0 | 0.04 | 0.04 | |
Net debt to EBITDA | 0.59 | 5.82 | 4.04 | 2.54 | 1.9 | |
Current ratio | 1.99 | 37.27 | 21.23 | 17.27 | 14.25 | |
Interest coverage | -1.32K | -7.78K | -14.09K | -114.79K | 0 | |
Income quality | 1.3 | 0.81 | 1.06 | 0.67 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.32 | 0 | 1.06 | 0 | 230.69 | |
Research and developement to revenue | 1.74 | 0 | 2.74 | 0 | 895.75 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.01 | 0.02 | 0.02 | 0.02 | |
Capex to revenue | -0.03 | 0 | -0.05 | 0 | -16.32 | |
Capex to depreciation | -1.3 | -1.06 | -2.71 | -1.84 | -3.02 | |
Stock based compensation to revenue | 0.01 | 0 | 0.58 | 0 | 190.48 | |
Graham number | 2.14 | 33.33 | 24.3 | 32.02 | 36.32 | |
ROIC | -1.32 | -0.18 | -0.24 | -0.38 | -0.47 | |
Return on tangible assets | -1.13 | -0.17 | -0.23 | -0.34 | -0.41 | |
Graham Net | 0.14 | 16.71 | 9.99 | 9.9 | 10.23 | |
Working capital | 4.44M | 260.54M | 239.59M | 269.22M | 322.92M | |
Tangible asset value | 5.45M | 261.72M | 243.17M | 277.42M | 332.21M | |
Net current asset value | 3.42M | 260M | 239.36M | 256.41M | 309.48M | |
Invested capital | 0.23 | 0 | 0 | 0.05 | 0.04 | |
Average receivables | 461K | 569K | 9.11M | 9.42M | 966K | |
Average payables | 1.29M | 2.12M | 2.9M | 3.49M | 4.39M | |
Average inventory | 379.5K | 1.12M | 2.27M | 1.11M | 6.61M | |
Days sales outstanding | 33.65 | 0 | 326.87 | 0 | 2.64K | |
Days payables outstanding | 43.93 | 1.3K | 1.48K | 754.63 | 2.44K | |
Days of inventory on hand | 15.97 | 889.27 | 1.24K | -190.07 | 6.29K | |
Receivables turnover | 10.85 | 0 | 1.12 | 0 | 0.14 | |
Payables turnover | 8.31 | 0.28 | 0.25 | 0.48 | 0.15 | |
Inventory turnover | 22.86 | 0.41 | 0.29 | -1.92 | 0.06 | |
ROE | -2.26 | -0.17 | -0.24 | -0.38 | -0.46 | |
Capex per share | -0.01 | -0.02 | -0.04 | -0.05 | -0.08 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | -1.09 | -1.15 | -1.27 | -1.33 | -1.34 | |
Operating cash flow per share | -0.78 | -1.21 | -1.04 | -1.15 | -0.85 | |
Free cash flow per share | -0.8 | -1.24 | -1.05 | -1.16 | -0.86 | |
Cash per share | 10.21 | 12.39 | 10.88 | 9.7 | 10.99 | |
Book value per share | 10.15 | 12.51 | 11.02 | 9.97 | 11.03 | |
Tangible book value per share | 10.15 | 12.51 | 11.02 | 9.97 | 11.03 | |
Share holders equity per share | 10.15 | 12.51 | 11.02 | 9.97 | 11.03 | |
Interest debt per share | 0.49 | 0.39 | 0.47 | 0.48 | 0.48 | |
Market cap | 1.31B | 1.21B | 1.19B | 945.82M | 1.2B | |
Enterprise value | 1.05B | 873.94M | 881.35M | 672.25M | 881.13M | |
P/E ratio | -11.04 | -9.25 | -7.93 | -6 | -7.44 | |
Price to sales ratio | 0 | 0 | 0 | 118.23K | 8.38K | |
POCF ratio | -61.2 | -35.38 | -38.58 | -27.83 | -47.05 | |
PFCF ratio | -60.21 | -34.32 | -38.19 | -27.39 | -46.07 | |
P/B Ratio | 4.73 | 3.41 | 3.65 | 3.2 | 3.61 | |
PTB ratio | 4.73 | 3.41 | 3.65 | 3.2 | 3.61 | |
EV to sales | 0 | 0 | 0 | 84.03K | 6.16K | |
Enterprise value over EBITDA | -35.21 | -24.52 | -23.62 | -15.53 | -22.03 | |
EV to operating cash flow | -48.8 | -25.53 | -28.59 | -19.78 | -34.61 | |
EV to free cash flow | -48.02 | -24.76 | -28.3 | -19.47 | -33.89 | |
Earnings yield | -0.02 | -0.03 | -0.03 | -0.04 | -0.03 | |
Free cash flow yield | -0.02 | -0.03 | -0.03 | -0.04 | -0.02 | |
Debt to equity | 0.05 | 0.04 | 0.04 | 0.05 | 0.04 | |
Debt to assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
Net debt to EBITDA | 8.94 | 9.47 | 8.26 | 6.32 | 7.92 | |
Current ratio | 17.27 | 23.43 | 20.77 | 18.23 | 14.25 | |
Interest coverage | 15.98K | 12.68 | 0 | 0 | 0 | |
Income quality | 0.72 | 0.96 | 0.82 | 0.86 | 0.63 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 1.14K | 63.67 | |
Research and developement to revenue | 0 | 0 | 0 | 4.27K | 262.19 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.03 | 0.01 | 0.02 | 0.02 | |
Capex to revenue | 0 | 0 | 0 | -68.75 | -3.78 | |
Capex to depreciation | -2.76 | -6.36 | -1.63 | -2.62 | -2.19 | |
Stock based compensation to revenue | 0 | 0 | 0 | 1.09K | 51.22 | |
Graham number | 15.76 | 18.03 | 17.73 | 17.27 | 18.21 | |
ROIC | -0.11 | -0.09 | -0.13 | -0.13 | -0.14 | |
Return on tangible assets | -0.1 | -0.09 | -0.11 | -0.12 | -0.11 | |
Graham Net | 9.14 | 11.54 | 10.07 | 8.96 | 10 | |
Working capital | 269.22M | 346.76M | 318.21M | 287.73M | 322.92M | |
Tangible asset value | 277.42M | 354.98M | 326.26M | 295.84M | 332.21M | |
Net current asset value | 256.41M | 332.77M | 304.26M | 274.03M | 309.48M | |
Invested capital | 0.05 | 0.04 | 0.04 | 0.05 | 0.04 | |
Average receivables | 493.5K | 993K | 1.05M | 931K | 994.5K | |
Average payables | 3M | 4.01M | 4.41M | 4.01M | 4.66M | |
Average inventory | 2.36M | 4.15M | 10.04M | 13.13M | 14.69M | |
Days sales outstanding | 0 | 0 | 0 | 10.1K | 686.64 | |
Days payables outstanding | 670.78 | 611.58 | 684.66 | 631.63 | 1.99K | |
Days of inventory on hand | -168.95 | 1.19K | 1.81K | 2.5K | 5.12K | |
Receivables turnover | 0 | 0 | 0 | 0.01 | 0.13 | |
Payables turnover | 0.13 | 0.15 | 0.13 | 0.14 | 0.05 | |
Inventory turnover | -0.53 | 0.08 | 0.05 | 0.04 | 0.02 | |
ROE | -0.11 | -0.09 | -0.11 | -0.13 | -0.12 | |
Capex per share | -0.01 | -0.04 | -0.01 | -0.02 | -0.02 |
KROS Frequently Asked Questions
What is Keros Therapeutics, Inc. stock symbol ?
Keros Therapeutics, Inc. is a US stock , located in Lexington of Ma and trading under the symbol KROS
Is Keros Therapeutics, Inc. buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $101.67. The lowest prediction is $80 and the highest is $120
What is KROS stock prediction ?
What is Keros Therapeutics, Inc. stock quote today ?
Keros Therapeutics, Inc. stock price is $66.1 today.
Is Keros Therapeutics, Inc. stock public?
Yes, Keros Therapeutics, Inc. is a publicly traded company.